-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] The eye is a very important sensory organ for human beings, and the management of eye health needs to be paid attention to
.
With the continuous improvement of domestic residents' awareness of eye health and the continuous enhancement of consumption willingness, it is expected that the ophthalmic medical industry will have a very broad space, reaching a market size of 100 billion yuan
.
Focusing on a considerable market, some ophthalmology companies have also made frequent moves
.
On April 12, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and sign "Fujian Shencheng" Letter of Intent on Equity Transfer
.
According to the letter of intent, Guangzheng Ophthalmology and Fujian Shencheng clearly stated that the 100% equity of Xintianshan is valued at RMB 72 million, and Fujian Shencheng intends to transfer 10% of Xintianshan's equity
.
The company said that the sale of this business will help accelerate the company's transformation and upgrading, and further implement the company's strategic goal of "Juli ophthalmic medical business"
.
It is worth mentioning that this is not the first time Guangzheng Ophthalmology has sold non-core assets.
As early as December 25, 2020, Guangzheng Ophthalmology issued two consecutive announcements to sell its assets, one of which plans to sell 100% of "Brighten Steel Machine".
Equity, valued at 200 million yuan
.
Guangzheng Steel Machinery is a subsidiary of Guangzheng Ophthalmology's wholly-owned subsidiary "Guangzheng Construction".
The company claims that this sale will help accelerate the company's transformation and upgrading, and further implement the company's "Juli ophthalmic medical business" development strategic goal; another The company plans to sell 100% equity of Hami An Schindler, a subsidiary of the company's wholly-owned subsidiary "Xintianshan", at a price of 10 million yuan
.
In addition, in 2020, Guangzheng Ophthalmology also had two asset transfer incidents, namely, in April 2020, it announced the transfer of "Shanshan Baoxuan" at a price of 24 million yuan, and in January 2020, it announced the transfer of "Guangzheng Equipment" at a price of 145 million yuan
.
In 2019, the company also had a sale of "Guangzheng Gas" for 567 million yuan
.
In fact, Guangzheng Ophthalmology's intention to focus on the ophthalmic medical field has been very strong.
Previously, on August 30, 2021, Guangzheng Ophthalmology stated on the investor interaction platform: the company has clarified the strategic development direction of "Juli ophthalmic medical business".
To continue to divest the auxiliary business; on April 1, 2022, Guangzheng Ophthalmology once again emphasized on the interactive platform that the company takes "cohesion of the ophthalmic medical business" as its strategic development direction and focuses on the ophthalmic medical business
.
The performance report shows that the operating income of Guangzheng Ophthalmology consists of three parts: ophthalmology, energy, and steel structure.
However, since 2018, the income of energy and steel structure business has declined, while the ophthalmology business has continued to rise, and its proportion in total revenue has also continued to increase.
.
From 2018 to the first half of 2020, the company's ophthalmology business revenue has increased from 38.
3% to 72.
27%
.
So, how big is the ophthalmic medical market that Guangzheng Ophthalmology is betting on? According to the industry, in the capital market, ophthalmology is indeed a highly prosperous segment of the medical industry, which is also an important logic to attract many large institutions to bet
.
Data shows that the overall size of the ophthalmology market in 2019 is 170 billion yuan, of which ophthalmic medical care accounts for 124 billion yuan, accounting for 73% of the entire ophthalmology market
.
In recent years, the market size of private eye hospitals has grown rapidly.
In 2018, the market size has reached 34.
16 billion yuan, and it is expected to reach 113.
22 billion yuan by 2024, with a compound annual growth rate of 21.
3%
.
At present, the companies in the ophthalmic medical service market mainly include Aier Ophthalmology and Guangzheng Ophthalmology, among which Aier Ophthalmology belongs to the head company.
The research report of CICC pointed out that in terms of revenue in 2020, Aier Ophthalmology accounted for about 30% of the private eye disease market.
32.
5% share, its position advantage is obvious
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
With the continuous improvement of domestic residents' awareness of eye health and the continuous enhancement of consumption willingness, it is expected that the ophthalmic medical industry will have a very broad space, reaching a market size of 100 billion yuan
.
Focusing on a considerable market, some ophthalmology companies have also made frequent moves
.
On April 12, Guangzheng Ophthalmology announced that in order to further implement the strategic development plan of "focusing on the ophthalmic medical business and accelerating the integration of auxiliary industries", the company plans to sell part of the equity of Xintianshan, a wholly-owned subsidiary, and sign "Fujian Shencheng" Letter of Intent on Equity Transfer
.
According to the letter of intent, Guangzheng Ophthalmology and Fujian Shencheng clearly stated that the 100% equity of Xintianshan is valued at RMB 72 million, and Fujian Shencheng intends to transfer 10% of Xintianshan's equity
.
The company said that the sale of this business will help accelerate the company's transformation and upgrading, and further implement the company's strategic goal of "Juli ophthalmic medical business"
.
It is worth mentioning that this is not the first time Guangzheng Ophthalmology has sold non-core assets.
As early as December 25, 2020, Guangzheng Ophthalmology issued two consecutive announcements to sell its assets, one of which plans to sell 100% of "Brighten Steel Machine".
Equity, valued at 200 million yuan
.
Guangzheng Steel Machinery is a subsidiary of Guangzheng Ophthalmology's wholly-owned subsidiary "Guangzheng Construction".
The company claims that this sale will help accelerate the company's transformation and upgrading, and further implement the company's "Juli ophthalmic medical business" development strategic goal; another The company plans to sell 100% equity of Hami An Schindler, a subsidiary of the company's wholly-owned subsidiary "Xintianshan", at a price of 10 million yuan
.
In addition, in 2020, Guangzheng Ophthalmology also had two asset transfer incidents, namely, in April 2020, it announced the transfer of "Shanshan Baoxuan" at a price of 24 million yuan, and in January 2020, it announced the transfer of "Guangzheng Equipment" at a price of 145 million yuan
.
In 2019, the company also had a sale of "Guangzheng Gas" for 567 million yuan
.
In fact, Guangzheng Ophthalmology's intention to focus on the ophthalmic medical field has been very strong.
Previously, on August 30, 2021, Guangzheng Ophthalmology stated on the investor interaction platform: the company has clarified the strategic development direction of "Juli ophthalmic medical business".
To continue to divest the auxiliary business; on April 1, 2022, Guangzheng Ophthalmology once again emphasized on the interactive platform that the company takes "cohesion of the ophthalmic medical business" as its strategic development direction and focuses on the ophthalmic medical business
.
The performance report shows that the operating income of Guangzheng Ophthalmology consists of three parts: ophthalmology, energy, and steel structure.
However, since 2018, the income of energy and steel structure business has declined, while the ophthalmology business has continued to rise, and its proportion in total revenue has also continued to increase.
.
From 2018 to the first half of 2020, the company's ophthalmology business revenue has increased from 38.
3% to 72.
27%
.
So, how big is the ophthalmic medical market that Guangzheng Ophthalmology is betting on? According to the industry, in the capital market, ophthalmology is indeed a highly prosperous segment of the medical industry, which is also an important logic to attract many large institutions to bet
.
Data shows that the overall size of the ophthalmology market in 2019 is 170 billion yuan, of which ophthalmic medical care accounts for 124 billion yuan, accounting for 73% of the entire ophthalmology market
.
In recent years, the market size of private eye hospitals has grown rapidly.
In 2018, the market size has reached 34.
16 billion yuan, and it is expected to reach 113.
22 billion yuan by 2024, with a compound annual growth rate of 21.
3%
.
At present, the companies in the ophthalmic medical service market mainly include Aier Ophthalmology and Guangzheng Ophthalmology, among which Aier Ophthalmology belongs to the head company.
The research report of CICC pointed out that in terms of revenue in 2020, Aier Ophthalmology accounted for about 30% of the private eye disease market.
32.
5% share, its position advantage is obvious
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
